Binge Eating Disorder - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Binge Eating Disorder - Pipeline Review, H2 2018’, provides an overview of the Binge Eating Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder

- The report reviews pipeline therapeutics for Binge Eating Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Binge Eating Disorder therapeutics and enlists all their major and minor projects

- The report assesses Binge Eating Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Binge Eating Disorder

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Chronos Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Novo Nordisk AS

Omeros Corp

Opiant Pharmaceuticals Inc

Sunovion Pharmaceuticals Inc

Chronos Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Novo Nordisk AS

Omeros Corp

Opiant Pharmaceuticals Inc

Sunovion Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Binge Eating Disorder – Overview

Binge Eating Disorder – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Binge Eating Disorder – Overview

Binge Eating Disorder – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Binge Eating Disorder – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Binge Eating Disorder – Companies Involved in Therapeutics Development

Chronos Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Novo Nordisk AS

Omeros Corp

Opiant Pharmaceuticals Inc

Sunovion Pharmaceuticals Inc

Binge Eating Disorder – Drug Profiles

ANS-6637 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-010018 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasotraline – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Saxenda – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx–480 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Binge Eating Disorder – Dormant Projects

Binge Eating Disorder – Discontinued Products

Binge Eating Disorder – Product Development Milestones

Featured News & Press Releases

Jul 25, 2018: Sunovion announces positive top-line results from pivotal study evaluating Dasotraline in adults with binge eating disorder

May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting

Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress

Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD

May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting

May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase

Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder

Oct 06, 2016: Study Finds New Approach to Block Binge Eating

Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Binge Eating Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Products under ...

List of Tables

Number of Products under Development for Binge Eating Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Binge Eating Disorder – Pipeline by Chronos Therapeutics Ltd, H2 2018

Binge Eating Disorder – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Binge Eating Disorder – Pipeline by Heptares Therapeutics Ltd, H2 2018

Binge Eating Disorder – Pipeline by Novo Nordisk AS, H2 2018

Binge Eating Disorder – Pipeline by Omeros Corp, H2 2018

Binge Eating Disorder – Pipeline by Opiant Pharmaceuticals Inc, H2 2018

Binge Eating Disorder – Pipeline by Sunovion Pharmaceuticals Inc, H2 2018

Binge Eating Disorder – Dormant Projects, H2 2018

Binge Eating Disorder – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Binge Eating Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Binge Eating Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports